CSL (ASX:CSL): Reset Year Signals Potential Turnaround After Strategic Restructuring

Aditi Sarkar

31 August 2026 10:04 PM AEST

CSL (ASX:CSL): Reset Year Signals Potential Turnaround After Strategic Restructuring

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CSL Limited (ASX:CSL) reported a statutory loss in FY2026 following significant Impairment and restructuring charges.
Underlying profit remained positive, supported by improving momentum in key Business areas.
The company completed the operational separation of its Seqirus vaccines business.
FY2027 growth expectations and improving immunoglobulin trends remain key investor focus areas.

CSL Limited (ASX:CSL) delivered a challenging but strategically important FY2026 result, with a statutory loss driven by significant impairment and restructuring charges, while investor focus shifted towards future growth prospects. The blood-products and vaccines company described the period as a reset year, highlighting operational changes and a renewed focus on returning to sustainable growth. The market reaction reflected expectations that the restructuring could support improved performance in future periods.

Latest Developments

CSL Limited (ASX:CSL) reported US$7.1 billion in pre-tax impairment and restructuring charges, primarily recorded during the second half, which contributed to a statutory net loss of approximately US$2.6 billion.

Excluding these impacts, Underlying Profit (NPATA) was around US$3.1 billion, down approximately 2%, with Revenue of about US$15.8 billion.

The company also confirmed the operational separation of its Seqirus vaccines business, allowing greater focus across its core operations. Interim chief executive Gordon Naylor highlighted that CSL had completed a major transformation phase and was positioned to pursue sustainable growth.

What the Numbers Show

CSL Limited (ASX:CSL)’s divisional performance showed varying trends across its operating segments. CSL Behring, the company’s largest business and representing approximately 72% of revenue, generated around US$11.4 billion in revenue, declining 1% year on year. However, immunoglobulin sales improved during the second half, increasing 7%.

The company’s haemophilia gene therapy HEMGENIX recorded growth of 25%, while hereditary angioedema products increased 14%, supporting momentum across selected therapeutic areas.

CSL Vifor increased revenue by approximately 3% to US$2.4 billion, supported by an 18% increase in nephrology dialysis products. However, iron products declined 16% due to generic competition.

Seqirus revenue declined 8% to approximately US$2.0 billion, although the company reported growth in seasonal influenza revenue during the period.

What Could Drive the Stock Next

CSL Limited (ASX:CSL)’s FY2027 outlook has become the key focus following the reset period. The company expects underlying profit growth of around 5% in FY2027, with revenue expected to remain broadly consistent with FY2026 on a constant-currency basis.

Improving immunoglobulin performance is an important Factor supporting the recovery outlook, as the business represents a significant part of CSL’s Earnings base. The completion of the Seqirus separation could also allow greater operational focus and efficiency.

The appointment of a permanent chief executive remains another factor investors will monitor as CSL moves into its next phase of growth.

Key Risks to Watch

CSL Limited (ASX:CSL) continues to face several operational and market challenges. CSL Vifor is expected to experience pressure in FY2027 due to increasing generic competition and the expiry of a US reimbursement benefit.

The company also remains exposed to regulatory and pricing conditions in key markets, including changes affecting albumin Demand in China. The large scale of impairments highlights the challenges associated with previous investments and strategic decisions.

Other risks include currency movements, plasma collection costs and uncertainty around the sustainability of the recovery in immunoglobulin demand. Meeting FY2027 growth expectations will be important in rebuilding market confidence.

Investor Takeaway

CSL Limited (ASX:CSL)’s FY2026 result reflected a period of significant restructuring, with accounting losses overshadowing continued underlying profitability. Investor attention has shifted towards the company’s forward guidance, operational improvements and signs of recovery across its core plasma business. The next phase will depend on CSL delivering its targeted growth, maintaining momentum in key therapies and demonstrating that the reset strategy is translating into sustainable earnings improvement.

FAQs

Q: Why did CSL report a statutory loss in FY2026?

A:CSL reported a statutory loss due to US$7.1 billion in impairment and restructuring charges.

Q: What was CSL’s underlying profit in FY2026?

A:Underlying profit (NPATA) was approximately US$3.1 billion.

Q: What is CSL’s FY2027 profit outlook?

A:CSL expects underlying profit growth of around 5% in FY2027.

Q: Which CSL business contributes the largest revenue share?

A:CSL Behring remains the company’s largest division, contributing approximately 72% of revenue.

Q: What are the key risks for CSL?

A:Key risks include pricing pressure, regulatory changes, currency movements, plasma costs and execution of the recovery strategy.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.